BUZZ-United Therapeutics shares soar after winning lawsuit against Liquidia

September 30 - ** The pharmaceutical company United Therapeutics UTHR.O saw its stock price rise by 13%, reaching $543.99

** The Federal Court in Delaware dismissed the “motion to dismiss” filed by Liquidia LQDA.O in its patent infringement case against United Therapeutics

** The core of this patent infringement lawsuit is whether Liquidia’s drug “Yutrepia” infringes the patent rights of United Therapeutics’ dry powder inhaled pulmonary disease medication “Tyvaso”

** “This ruling is a significant positive for UTH (United Therapeutics),” said RBC Capital analyst Lisa Walter, adding that the decision “casts a heavy shadow on Yutrepia’s path to competition”

** The judge stated that United Therapeutics had fully disclosed its “joint ownership” argument and had given Liquidia sufficient notice regarding this defense

** “This is a key factor for Liquidia in this case, and dismissing the ‘motion to dismiss’ will have a negative impact on the final judgement of the case,” said an analyst from Raymond James

** Liquidia’s shares were halted during afternoon trading

** As of the previous trading day’s close, UTHR has risen 10.7% year-to-date

(To facilitate non-native English speakers, Reuters has made this report available via automated translation into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of translated text. Automated translations are provided solely for reader convenience. Reuters is not responsible for any harm or loss resulting from the use of the automated translation feature.)